Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis : A multi-institutional retrospective study
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). However, whether micronecrosis can optimize HCC staging systems remains unilluminated. A total of 1632 HCC patients who underwent curative hepatectomy in four institutions from January 2014 to December 2021 were enrolled in this study. Independent prognostic factors were identified, and optimized staging models were established using a training cohort (n = 934). The performance of optimized staging models was validated using an external cohort consisting of cases from three other institutions (n = 232). In addition, patients from our prospectively collected database (n = 379) tested the application effectiveness of the models. Harrel's c-statistics and the corrected Akaike information criterion (AICc) were used to assess the performance of staging models. In most of Barcelona Clinic Liver Cancer (BCLC) and tumor (T) stages, HCC patients with tumor micronecrosis showed poorer prognosis than those without. Tumor micronecrosis, microvascular invasion, multiple tumors and tumor size >2 cm were independent prognostic-related factors. The BCLC and T staging models incorporating tumor micronecrosis showed better performance than the original systems (c-statistic, 0.712 and 0.711 vs. 0.664 and 0.679; AICc, 2314.8 and 2322.3 vs. 2338.2 and 2338.1; respectively). Furthermore, the external validation cohort confirmed that the optimized staging models had improved efficiency compared with the original ones. Moreover, the prospective cohort demonstrated the applicability of the optimized staging systems. Tumor micronecrosis plays a stage-ascending role in HCC patients. The BCLC and T staging systems incorporating tumor micronecrosis can improve the prognosis stratification efficiency of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:585 |
|---|---|
| Enthalten in: |
Cancer letters - 585(2024) vom: 31. März, Seite 216654 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yangyang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BCLC |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2024.216654 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367627582 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367627582 | ||
| 003 | DE-627 | ||
| 005 | 20240305232238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2024.216654 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM367627582 | ||
| 035 | |a (NLM)38272344 | ||
| 035 | |a (PII)S0304-3835(24)00048-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yangyang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis |b A multi-institutional retrospective study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). However, whether micronecrosis can optimize HCC staging systems remains unilluminated. A total of 1632 HCC patients who underwent curative hepatectomy in four institutions from January 2014 to December 2021 were enrolled in this study. Independent prognostic factors were identified, and optimized staging models were established using a training cohort (n = 934). The performance of optimized staging models was validated using an external cohort consisting of cases from three other institutions (n = 232). In addition, patients from our prospectively collected database (n = 379) tested the application effectiveness of the models. Harrel's c-statistics and the corrected Akaike information criterion (AICc) were used to assess the performance of staging models. In most of Barcelona Clinic Liver Cancer (BCLC) and tumor (T) stages, HCC patients with tumor micronecrosis showed poorer prognosis than those without. Tumor micronecrosis, microvascular invasion, multiple tumors and tumor size >2 cm were independent prognostic-related factors. The BCLC and T staging models incorporating tumor micronecrosis showed better performance than the original systems (c-statistic, 0.712 and 0.711 vs. 0.664 and 0.679; AICc, 2314.8 and 2322.3 vs. 2338.2 and 2338.1; respectively). Furthermore, the external validation cohort confirmed that the optimized staging models had improved efficiency compared with the original ones. Moreover, the prospective cohort demonstrated the applicability of the optimized staging systems. Tumor micronecrosis plays a stage-ascending role in HCC patients. The BCLC and T staging systems incorporating tumor micronecrosis can improve the prognosis stratification efficiency of patients | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BCLC | |
| 650 | 4 | |a Disease staging | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a TNM | |
| 650 | 4 | |a Tumor micronecrosis | |
| 700 | 1 | |a Sun, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Cao |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Hongbin |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Juhui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Enliang |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Zhixiong |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Qihan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xuqi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jiangchao |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Mao |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Wanyue |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qitai |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Xiaobao |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wenyong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Linquan |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Yongyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Tingbo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 585(2024) vom: 31. März, Seite 216654 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:585 |g year:2024 |g day:31 |g month:03 |g pages:216654 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216654 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 585 |j 2024 |b 31 |c 03 |h 216654 | ||